Project Description

EpiBone
Developing The Technology To Grow New Bone.

Date & Time:

February 18, 12:00 PM ET / 9:00 AM PT
Webinar: Details provided upon RSVP approval

About the Event:

EpiBone is on a mission to use groundbreaking research to transform skeletal repair.

They do that by doing something that until recently was thought impossible: they grow bones in their lab and then implant that individually-modeled, living bone into the patient who needs it. So now, after a decade of work, EpiBone is ready to deliver on the promise of personalized medicine.

The EpiBone Process:
  • 3D imaging precisely maps the shape and size of bone needed
  • Adult stem cells are extracted from the patient’s abdominal fat
  • The cells are placed on a scaffold created from the 3D image of the bone
  • The scaffold is placed in a bioreactor that nurtures cell growth
  • Over the next three weeks, the cells remodel into a personalized bone graft ready for implantation

Once implanted the bone continues to grow, integrating itself into the body. It is as natural as the original bone around it. Beginning with facial reconstruction, EpiBone’s technology will ultimately be used for joint repair as well as any other bone repair or replacement.

The technology is so promising it has received support from Henry Kravis, The Tata Family Office, and MIT’s Dr. Robert Langer who has been involved with Moderna since its earliest days.

Join our webinar on February 18 to hear about this groundbreaking technology from EpiBone CEO and co-founder, Dr. Nina Tandon and its incredible promise to transform skeletal repair.

Share this Event

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.